Please assess the completion status of the following clinical trial:

Trial Title: CHemoImmunotherapy With Early Central Nervous System (CNS) Prophylaxis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 - \< 65 years. Histologically confirmed CD20+ diffuse large B-cell lymphoma (DLBCL) based on WHO 2008 Lymphoma Classification~* Follicular lymphomas (FLs) grade 3b is allowed~Patients in at least stage II with age adjusted international prognostic score (IPI score) of 2 or 3:~* Stage III /IV and elevated LDH~* Stage III/IV and WHO performance status 2 - 3~* Stage II and elevated LDH and WHO performance status 2 - 3 And/or patients with~* More than one extranodal site~* Testicular lymphoma, stage IIE and higher~* Paranasal sinus and orbital lymphoma with destruction of bone~* Large cell infiltration of the bone marrow~Exclusion Criteria:~* Severe cardiac disease: cardiac function grade 3-4~* Impaired liver, renal or other organ function not caused by lymphoma, which will interfere with the treatment schedule~* Pregnancy/lactation~* Men and women of reproductive potential not agreeing to use an acceptable method of birth control during treatment and for six months after completion of treatment~* Patients with other severe medical problems and with an expected short survival for non-lymphoma reasons~* Known HIV positivity~* Uncontrolled infectious disease, including meningeal infection~* Active cancer except basal cell carcinoma and cervical carcinoma in situ during the last five years~* Earlier treatment containing anthracyclins~* Psychiatric or mental disorder which make the patient unable to give an informed consent and/or adhere to the protocol~* CNS disease as diagnosed by MRI or cerebrospinal fluid (CSF) cytology. Positive CSF flow cytometry below diagnostic threshold level by cytology is allowed~* Pleural or peritoneal fluid that cannot be drained safely~* Hypersensitivity to the active substance or any of the other ingredients~* Patients participating in other clinical studies, unless followed for survival

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- CNS prophylaxis (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).